Navigation Links
/C O R R E C T I O N -- Clinical Therapeutics/
Date:9/10/2009

In the news release, "Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section" issued on 9 Sep 2009 08:30 GMT, by Clinical Therapeutics over PR Newswire, we are advised by a representative of the company that the Dateline has been changed from "Bridgewater, England" to "Bridgewater, New Jersey" and the contact number has been changed from +44(0)908-547-2094 to +1-908-547-2094 which were incorrectly transmitted by PR Newswire. Complete, corrected release follows:

, /PRNewswire/ -- Clinical Therapeutics,( http://www.clinicaltherapeutics.com/) the world's premier, rapid-publication journal, is proud to announce the addition of Michael G. Spigarelli, MD, PhD, to our distinguished editorial board.

As section editor for the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section (formerly the Pediatric Research section), Dr. Spigarelli brings a wealth of knowledge and a strong background in addressing the issues surrounding these special populations. He completed his residency in internal medicine and pediatrics at the University of Michigan Medical Center in Ann Arbor and his fellowship in adolescent medicine at Cincinnati Children's Hospital Medical Center, where he currently remains on staff.

Pregnant women and children remain among the most vulnerable patients undergoing therapy today due to a lack of critical information on the safety, tolerability, and efficacy of pharmacotherapies indicated for them. As Dr. Spigarelli states in his inaugural editorial, "To date, most medications used in the treatment of illness in children have never been tested in them.... This lack of crucial information has important implications for a variety of stakeholders."

By refocusing the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section, Clinical Therapeutics(http://www.clinicaltherapeutics.com/) seeks to become the premier venue for publication of clinical research in these special populations and serve as an international forum for the timely discussion of safe and effective drug therapies in neonates, infants, children, adolescents, and pregnant or lactating women.

"As Editor of this section, I encourage each of you to review your files for data already obtained but not yet published, for data from ongoing studies, and consider submitting those manuscripts to Clinical Therapeutics. Each additional piece of available data adds to the knowledge base needed to provide the best health care for pregnant women and children."

An example of important pediatric information published by the journal is the supplemental issue on Conquering Pain: The Hidden Cost of Immunization sponsored by the Canadian Institutes of Health Research and the SickKids Foundation. Also highlighting the journal's commitment to fostering publication of scientific research related to these special populations is the upcoming focus issue on vaccines.

Articles can be submitted online or directly to clinther@elsevier.com; click here for Information for Authors (http://www.clinicaltherapeutics.com/ifa3.html).

For more information about this press release and Clinical Therapeutics, contact Julie E. Artim at:

    Phone: +1-908-547-2094
    Email: ELSRapidPubs@Elsevier.com
    Website: ElsRapidPubs.com


------

Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section

BRIDGEWATER, England, September 9 /PRNewswire/ -- Clinical Therapeutics,( http://www.clinicaltherapeutics.com/) the world's premier, rapid-publication journal, is proud to announce the addition of Michael G. Spigarelli, MD, PhD, to our distinguished editorial board.

As section editor for the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section (formerly the Pediatric Research section), Dr. Spigarelli brings a wealth of knowledge and a strong background in addressing the issues surrounding these special populations. He completed his residency in internal medicine and pediatrics at the University of Michigan Medical Center in Ann Arbor and his fellowship in adolescent medicine at Cincinnati Children's Hospital Medical Center, where he currently remains on staff.

Pregnant women and children remain among the most vulnerable patients undergoing therapy today due to a lack of critical information on the safety, tolerability, and efficacy of pharmacotherapies indicated for them. As Dr. Spigarelli states in his inaugural editorial, "To date, most medications used in the treatment of illness in children have never been tested in them.... This lack of crucial information has important implications for a variety of stakeholders."

By refocusing the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section, Clinical Therapeutics(http://www.clinicaltherapeutics.com/) seeks to become the premier venue for publication of clinical research in these special populations and serve as an international forum for the timely discussion of safe and effective drug therapies in neonates, infants, children, adolescents, and pregnant or lactating women.

"As Editor of this section, I encourage each of you to review your files for data already obtained but not yet published, for data from ongoing studies, and consider submitting those manuscripts to Clinical Therapeutics. Each additional piece of available data adds to the knowledge base needed to provide the best health care for pregnant women and children."

An example of important pediatric information published by the journal is the supplemental issue on Conquering Pain: The Hidden Cost of Immunization sponsored by the Canadian Institutes of Health Research and the SickKids Foundation. Also highlighting the journal's commitment to fostering publication of scientific research related to these special populations is the upcoming focus issue on vaccines.

Articles can be submitted online or directly to clinther@elsevier.com; click here for Information for Authors (http://www.clinicaltherapeutics.com/ifa3.html).

For more information about this press release and Clinical Therapeutics, contact Julie E. Artim at:

    Phone: +44(0)908-547-2094
    Email: ELSRapidPubs@Elsevier.com
    Website: ElsRapidPubs.com



'/>"/>
SOURCE Clinical Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 , ... Bactana Animal Health, ... in the world’s food supply through enhancement of the gut microbiota, today announced the ... Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and a number ...
(Date:3/29/2017)... -- Research and Markets has announced the addition ... report to their offering. ... The study scope includes key ... interference, synthetic biology tools and genome editing tools); synthetic biology-enabled ... technologies and products are analyzed to determine present and future ...
(Date:3/28/2017)... ... March 28, 2017 , ... Franz Inc ., the leading supplier ... has been named a ‘Champion’ by Bloor Research in its recent Graph Database ... its class, and, thanks to Gruff, it was rated as the easiest product to ...
(Date:3/28/2017)... WASHINGTON , March 28, 2017 /PRNewswire/ ... launch single-cell sequencing during the American Association for Cancer ... Convention Center in Washington, D.C. , ... differential gene expression of thousands of cells at the ... Experts on-hand at AACR to discuss ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
Breaking Biology News(10 mins):